Skip to main content

Market Overview

Veru's VERU-111 Moves Into Pivotal COVID-19 Study


Veru Inc (NASDAQ: VERUwill start testing VERU-111 in the registrational Phase 3 study in hospitalized patients who have COVID-19 virus infection and are at high risk for Acute Respiratory Distress Syndrome.

  • Mitchell Steiner, chairman, president, and CEO, said, "we have the resources to conduct a Phase 3 trial without impacting our cancer drugs' clinical development."
  • Recently, the company raised gross proceeds of approximately $100 million via secondary equity offering.
  • The company will seek funding from The Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services.
  • The 400-subject Phase 3 study will evaluate daily oral doses of VERU-111 versus placebo with the primary efficacy endpoint of the proportion of patients alive at Day 29.
  • The trial will start next month and results expected by the end of this year.
  • Price Action: VERU shares are trading 2.75% higher at $14.20 on the last check Monday.

Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: Acute Respiratory Distress Syndrome Covid-19Biotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at